Trial Outcomes & Findings for A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest (APACAR2) (NCT NCT02527031)
NCT ID: NCT02527031
Last Updated: 2026-06-30
Results Overview
The time frame for this outcome is unique for one patient. This criterion is fulfilled if the patient is alive with a CPC 1 or 2 at the discharge from the ICU (on a average time of 6 weeks) or if he is alive at 6 months with a CPC 1 or 2.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
65 participants
Primary outcome timeframe
At 6 months or participants will be followed for the duration of hospital stay, an expected average of 6 weeks
Results posted on
2026-06-30
Participant Flow
65 patients were enrolled across 3 centers in France between March 2016 and February 2019.
Participant milestones
| Measure |
In Hospital ECMO
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
Pre Hospital ECMO
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
Overall Study
STARTED
|
33
|
32
|
|
Overall Study
COMPLETED
|
31
|
31
|
|
Overall Study
NOT COMPLETED
|
2
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Randomized patients without any missing values
Baseline characteristics by cohort
| Measure |
In Hospital ECMO
n=33 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
Pre Hospital ECMO
n=32 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
Total
n=65 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
49 years
STANDARD_DEVIATION 11 • n=30 Participants • Randomized patients without any missing values
|
48 years
STANDARD_DEVIATION 12 • n=30 Participants • Randomized patients without any missing values
|
49 years
STANDARD_DEVIATION 11 • n=60 Participants • Randomized patients without any missing values
|
|
Sex: Female, Male
Female
|
4 Participants
n=33 Participants
|
3 Participants
n=32 Participants
|
7 Participants
n=65 Participants
|
|
Sex: Female, Male
Male
|
29 Participants
n=33 Participants
|
29 Participants
n=32 Participants
|
58 Participants
n=65 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
No Flow duration (minutes)
|
0 minutes
n=29 Participants • Randomized patients without any missing values.
|
0 minutes
n=29 Participants • Randomized patients without any missing values.
|
0 minutes
n=58 Participants • Randomized patients without any missing values.
|
PRIMARY outcome
Timeframe: At 6 months or participants will be followed for the duration of hospital stay, an expected average of 6 weeksPopulation: The intention-to-treat (ITT) population included all randomized patients.
The time frame for this outcome is unique for one patient. This criterion is fulfilled if the patient is alive with a CPC 1 or 2 at the discharge from the ICU (on a average time of 6 weeks) or if he is alive at 6 months with a CPC 1 or 2.
Outcome measures
| Measure |
Pre Hospital ECMO
n=32 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=33 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
Number of Participants Surviving With Good Neurological Outcome (CPC 1 or 2) on Discharge From the ICU or at 6 Months
|
7 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: During ECMO implementation, up to 2 hoursPopulation: The analysis was performed on the complete case dataset, including all randomized patients without any missing values.
Success of implementation is defined as a flow rate more than 2 Liters / minutes
Outcome measures
| Measure |
Pre Hospital ECMO
n=31 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=24 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
Number of Participants With Success of the Implementation of ECMO
|
27 Participants
|
17 Participants
|
SECONDARY outcome
Timeframe: From incision to pump started, up to 2 hoursPopulation: The analysis was performed on the complete case dataset, including all randomized patients without any missing values.
Time between incision and pomp started
Outcome measures
| Measure |
Pre Hospital ECMO
n=31 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=22 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
ECMO Implementation Time
|
20 minutes
Interval 17.0 to 25.0
|
18 minutes
Interval 13.0 to 22.0
|
SECONDARY outcome
Timeframe: One dayPopulation: The analysis was performed on the complete case dataset, including all randomized patients without any missing values.
Haemorrhage defined by more than 6 transfusions of packed red blood cells in the first 24 hours
Outcome measures
| Measure |
Pre Hospital ECMO
n=22 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=25 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
Number of Participants With Immediate Complications: Haemorrhage
|
6 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: One dayPopulation: The analysis was performed on the complete case dataset, including all randomized patients without any missing values.
Outcome measures
| Measure |
Pre Hospital ECMO
n=25 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=26 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
Number of Participants With Immediate Complications: Infection
|
9 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: 28 daysPopulation: The analysis was performed on the complete case dataset, including all randomized patients without any missing values.
Number of participants surviving with good neurological outcome (CPC 1 or 2) at 28 days
Outcome measures
| Measure |
Pre Hospital ECMO
n=30 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=31 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
The Quality of Survivors' Neurological Status According to the CPC Neurological Classification at Day 28
|
5 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: 2 monthsPopulation: The analysis was performed on the complete case dataset, including all randomized patients without any missing values.
Number of participants surviving with good neurological outcome (CPC 1 or 2) at 2 months.
Outcome measures
| Measure |
Pre Hospital ECMO
n=31 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=33 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
The Quality of Survivors' Neurological Status According to the CPC Neurological Classification at 2 Months
|
5 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: The analysis was performed on the complete case dataset, including all randomized patients without any missing values.
Number of participants surviving with good neurological outcome (CPC 1 or 2) at 1 year
Outcome measures
| Measure |
Pre Hospital ECMO
n=31 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=31 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
The Quality of Survivors' Neurological Status According to the CPC Neurological Classification at 1 Year
|
5 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: 6 monthsPopulation: The analysis was performed on the complete case dataset, including all randomized patients without any missing values.
Number of participants with at least one organ harvested when patient progressing towards brain death
Outcome measures
| Measure |
Pre Hospital ECMO
n=32 Participants
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
In Hospital ECMO
n=33 Participants
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
Number of Organ Harvesting
|
1 Participants
|
0 Participants
|
Adverse Events
In Hospital ECMO
Serious events: 26 serious events
Other events: 0 other events
Deaths: 24 deaths
Pre Hospital ECMO
Serious events: 24 serious events
Other events: 0 other events
Deaths: 26 deaths
Serious adverse events
| Measure |
In Hospital ECMO
n=33 participants at risk；n=28 participants at risk
ECMO Insertion on in hospital setting for a refractory cardiac arrest
|
Pre Hospital ECMO
n=32 participants at risk；n=30 participants at risk
ECMO Insertion on pre hospital setting for a refractory cardiac arrest
|
|---|---|---|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
39.3%
11/28 • Number of events 11 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
26.7%
8/30 • Number of events 8 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Cardiac disorders
Cardiac failure acute
|
35.7%
10/28 • Number of events 10 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
30.0%
9/30 • Number of events 9 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Cardiac disorders
Cardiac tamponade
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Gastrointestinal disorders
Abdominal compartment syndrome
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
3.3%
1/30 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
7.1%
2/28 • Number of events 2 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Gastrointestinal disorders
Peritoneal haematoma
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Hepatobiliary disorders
Hepatic failure
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Infections and infestations
Catheter site infection
|
7.1%
2/28 • Number of events 2 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
6.7%
2/30 • Number of events 2 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Infections and infestations
Pneumonia
|
25.0%
7/28 • Number of events 7 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
16.7%
5/30 • Number of events 5 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Infections and infestations
unknown site
|
0.00%
0/28 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
3.3%
1/30 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/28 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
3.3%
1/30 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Injury, poisoning and procedural complications
Cardiac procedure complication
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/28 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
3.3%
1/30 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Injury, poisoning and procedural complications
Vascular access site thrombosis
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Injury, poisoning and procedural complications
Vascular injury
|
7.1%
2/28 • Number of events 2 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
13.3%
4/30 • Number of events 4 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Metabolism and nutrition disorders
Lactic acidosis
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
0.00%
0/28 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
6.7%
2/30 • Number of events 2 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Nervous system disorders
Brain oedema
|
0.00%
0/28 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
6.7%
2/30 • Number of events 2 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Nervous system disorders
Cerebral haemorrhage
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Renal and urinary disorders
Renal failure
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
10.0%
3/30 • Number of events 3 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema
|
10.7%
3/28 • Number of events 3 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
10.0%
3/30 • Number of events 3 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.00%
0/28 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
3.3%
1/30 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Respiratory, thoracic and mediastinal disorders
Haemothorax
|
0.00%
0/28 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
3.3%
1/30 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Respiratory, thoracic and mediastinal disorders
Mediastinal haematoma
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
7.1%
2/28 • Number of events 2 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Surgical and medical procedures
Amputation
|
0.00%
0/28 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
6.7%
2/30 • Number of events 2 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Vascular disorders
Haemorrhage
|
50.0%
14/28 • Number of events 14 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
60.0%
18/30 • Number of events 18 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Vascular disorders
Peripheral artery thrombosis
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Vascular disorders
Peripheral ischaemia
|
10.7%
3/28 • Number of events 3 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
30.0%
9/30 • Number of events 9 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Vascular disorders
Post procedural complication circulatory
|
3.6%
1/28 • Number of events 1 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
0.00%
0/30 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
|
Vascular disorders
Shock
|
39.3%
11/28 • Number of events 11 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
36.7%
11/30 • Number of events 11 • 12 months
The number of participants at risk can be different for to All-Cause mortality and serious adverse events because the data is missing for a different number of participants. For example, all-cause mortality at 12 months cannot be estimate for the 2 participants loss of follow up in the In-hospital ECMO group, the number at risk is 31. As the serious adverse events were evaluated in ICU and not at 12 months, the number at risk can be different than those of all-cause mortality. For each serious
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place